Irving and Betty Brudnick Professor of Psychiatry, Director, UMass Depression Center
Psychiatry
Dr. Anthony J. Rothschild, MD
|
|
Give Review
Doctor Anthony J. Rothschild, MD works in the field of Psychiatry. He researched medicine at Perelman School of Medicine at the University of Pennsylvania. Anthony Rothschild has written publications. He has 97 publications published with PubMed. The lastest publication is: 'Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Rating scales measuring the severity of psychotic depression.
- The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.
- Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).
- Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis.
- Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.
- Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial.
- Vagus Nerve Stimulation and Food Intake: Effect of Body Mass Index.
- Differential impact of Anxiety symptoms and Anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.
- Measuring treatment response in psychotic depression: The Psychotic Depression Assessment Scale (PDAS) takes both Depressive and psychotic symptoms into account.
- Persistent delusional theme over 13 episodes of psychotic depression.
- Risk factors for suicide among 34,671 patients with psychotic and non-psychotic severe depression.
- Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive Disorder treated with venlafaxine extended re...
- The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with Major depressive disor...
- Antidepressant Augmentation Using the N-Methyl-d-Aspartate Antagonist Memantine: A Randomized, Double-Blind, Placebo-Controlled Trial.
- A Gender Analysis of the Study of Pharmacotherapy of Psychotic Depression (STOP-PD): Gender and Age as Predictors of Response and Treatment-Associated Changes in Body ...
- Challenges in the Treatment of Major Depressive Disorder With Psychotic Features.
- Sexual Functioning in Patients With Recurrent Major Depressive Disorder Enrolled in the PREVENT Study.
- GABAergic neuroactive steroids and resting-state functional connectivity in postpartum depression: A preliminary study.
- Vortioxetine (Lu AA21004) 5mg in generalized Anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
- Progression of female reproductive stages associated with Bipolar illness exacerbation.
- Manic episode after total abdominal hysterectomy with bilateral salpingo-oophorectomy: case report.
- Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.
- Relationships between multiple sclerosis and depression.
- Assessing Rates and Predictors of Tachyphylaxis During the Prevention of Recurrent Episodes of Depression With Venlafaxine ER for Two Years (PREVENT) Study.
- The Rothschild Scale for Antidepressant Tachyphylaxis: reliability and validity.
- Correlates of suicidality among patients with psychotic depression.
- The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
- The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.
- Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study.
- A review of postpartum psychosis.
- Placebo response in psychotic depression.
- Conflict-of-interest charge.
- A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for Major depression with psychotic features.
- Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in Major depression.
- Challenges in the treatment of depression with psychotic features.
- How long should patients with psychotic depression stay on the antipsychotic medication?
- An open label trial of C-1073 (mifepristone) for psychotic Major depression.
- Relationships between brain CT scan findings and cortisol in psychotic and nonpsychotic depressed patients.
- Sexual side effects of antidepressants.
- Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus.
- Serotonin activity in psychotic (delusional) Major depression.
- Fluctuating postdexamethasone cortisol levels in a patient with melancholia.
- Comparison of the frequency of behavioral disinhibition on alprazolam, clonazepam, or no benzodiazepine in hospitalized psychiatric patients.
- The dexamethasone suppression test: identification of subtypes of depression.
- The dexamethasone suppression test as a discriminator among subtypes of psychotic patients.
- Delusional depression, family history, and DST response: a pilot study.
- The DST in psychotic depression: diagnostic and pathophysiologic implications.
- The dexamethasone suppression test in normal control subjects: comparison of two assays and effect of age.
- Platelet MAO activity and the dexamethasone suppression test in depressed patients.
- Postdexamethasone cortisol levels and subgroups of affective illness.
- Psychotic and nonpsychotic depressions: I. Comparison of plasma catecholamines and cortisol measures.
- Theoretical basis for response to steroid suppression in Major depression.
- Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday.
- Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study.
- Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia.
- Depression secondary to Anxiety: findings from the McLean Hospital Depression Research Facility.
- Management of psychotic, treatment-resistant depression.
- The roles of glucocorticoid and dopaminergic systems in delusional (psychotic) depression.
- On psychotic Major depression.
- Olanzapine and haloperidol in first episode psychosis: two-year data.
- Dexamethasone elevates dopamine in human plasma and rat brain.
- Dexamethasone increases plasma free dopamine in man.
- Psychotic and nonpsychotic depressions: II. Platelet MAO activity, plasma catecholamines, cortisol, and specific symptoms.
- Selective serotonin reuptake inhibitors and delusional depression.
- Toward a biochemical classification of depressive Disorders IX. DST results and platelet MAO activity.
- Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments.
- Delirium: an SSRI-benztropine adverse effect?
- Disinhibition, amnestic reactions, and other adverse reactions secondary to triazolam: a review of the literature.
- Polysomnographic characteristics of young manic patients. Comparison with unipolar depressed patients and normal control subjects.
- The diagnosis and treatment of late-life depression.
- New directions in the treatment of antidepressant-induced sexual dysfunction.
- The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain.
- Psychiatrists' responses to failure of maintenance therapy with antidepressants.
- GKAP, a novel synaptic protein that interacts with the guanylate kinase-like domain of the PSD-95/SAP90 family of channel clustering molecules.
- Clustering of Shaker-type K+ channels by interaction with a family of membrane-associated guanylate kinases.
- Mania after withdrawal of isocarboxazid.
- Combining treatments for depression.
- Heteromultimerization and NMDA receptor-clustering activity of Chapsyn-110, a member of the PSD-95 family of proteins.
- Advances in the management of depression: implications for the obstetrician/gynecologist.
- Acute cardiovascular effects of tranylcypromine: correlation with plasma drug, metabolite, norepinephrine, and MHPG levels.
- The nifedipine gastrointestinal therapeutic system in the treatment of hypertension.
- Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiv...
- [Causes of death of children at the Hôpital des Enfants-Malades. Statistical study of 1 098 pathologic and clinical records collected from 1966 to 1975 (author's trans...
- Correlation between patient and clinician assessments of depression severity in the PREVENT study.
- Effect of age on the frequency of Anxiety disorders in major depression with psychotic features.
- Psychosocial outcomes in patients with recurrent major depressive Disorder during 2 years of maintenance treatment with venlafaxine extended release.
- Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive Disorder.
- A delusion assessment scale for psychotic Major depression: Reliability, validity, and utility.
- Psychiatric outcomes following medical and surgical abortion.
- Persisting low use of antipsychotics in the treatment of major depressive Disorder with psychotic features.
- Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic.
- A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic...
- Missed diagnosis of psychotic depression at 4 academic medical centers.
- Weight gain during olanzapine treatment for psychotic depression: effects of dose and age.
- Does major depressive Disorder with somatic delusions constitute a distinct subtype of major depressive Disorder with psychotic features?
- Neuropsychological deficits in psychotic versus nonpsychotic Major depression and no mental illness.
Schools
Univ Of Pa Sch Of Med
Mt Auburn Mass Genl Hospital
McLean Hospital
Procedures Preformed
- Psychiatric Evaluation
Conditions Treated
- Anorexia
- Anxiety
- Bipolar Disorder
- Eating Disorders
- View All
Doctors Specialties
- Psychiatry
Accepted Insurances
Education
-
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
UMass Memorial Medical Center
Drug Facts
| NPI NUMBER | 1841278488 | |
| NPPES Provider LastName | ROTHSCHILD | |
| NPPES Provider FirstName | ANTHONY | |
| NPPES Provider ZIPCode | 016052323 | |
| NPPES Provider State | MA | |
| Specialty Description | Psychiatry | |
| Total Claim Count | 185.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841278488 |
| Last Name Of The Provider | ROTHSCHILD |
| First Name Of The Provider | ANTHONY |
| View All |
Similar Doctors
|
|
Dr. Anil V. Vatsavayi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daron C. Massey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robyn Treadwell, MD |
|
|
Dr. Daniel F. Rowe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eduardo J. Caussade-Rodriguez, MD |
|
|
Dr. Deborah C. Field, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary K. Wilber, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimberlee A. Kusiak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ludmilla L. Tonkonogy, MD |
|
|
Dr. Philip R. Burke, MD
This Doctor is OpenDoctor Recommended.
|